NCT01835496View on ClinicalTrials.gov

Absorption, Metabolism, and Excretion of a Single Dose of Ferriprox® in Patients With Sickle Cell Disease

PHASE1CompletedINTERVENTIONAL
Enrollment

8

Participants

Timeline

Start Date

May 31, 2013

Primary Completion Date

April 30, 2014

Study Completion Date

April 30, 2014

Conditions
Sickle Cell Disease
Interventions
DRUG

single 1500 mg dose of Ferriprox

A single dose of 1500mg of Ferriprox (three 500mg tablets) administered under fasting conditions

Trial Locations (1)

H2L 4M1

CHUM-Hôpital Notre-Dame, Montreal

Sponsors

Lead Sponsor

ApoPharma
All Listed Sponsors
lead

ApoPharma

INDUSTRY

NCT01835496 - Absorption, Metabolism, and Excretion of a Single Dose of Ferriprox® in Patients With Sickle Cell Disease | Biotech Hunter | Biotech Hunter